DUBLIN, Ireland — Horizon Pharma plc plans to acquire Crealta Holdings LLC for $510 million in cash. Horizon said the deal will bring the company Krystexxa (pegloticase), the first and only Food and Drug Administration-approved drug for chronic refractory gout. “The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated, long-life medicines
DUBLIN, Ireland — Horizon Pharma plc is moving its U.S. corporate headquarters to a larger facility in Lake Forest, Ill., to accommodate its expanding organization. Horizon said Monday that the new office space, located at 150 South Saunders Rd. in Lake Forest, is about triple the size of its current U.S. headquarters in Deerfield, Ill., and
DUBLIN, Ireland, and BRISBANE, Calif. — Horizon Pharma plc plans to acquire biopharmaceutical company Hyperion Therapeutics Inc. in a $1.1 billion cash deal. Horizon said Monday that the agreement will increase its number of products from five to seven, notably through the addition of Ravicti and Buphenyl to its orphan business unit. Ravicti and Buphenyl
